Browsing by Author Seymour, John F.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 11 of 11
Issue DateTitleAuthor(s)Citation
2005Autografting followed by rituximab for chemosensitive mantle cell lymphoma: A pilot study and literature review.Hertzberg, Mark; Bashford, J.; Gill, D.; Grigg, Andrew P.; Marlton, P.; Norris, D.; Saal, R.; Seymour, John F.; Shuttleworth, P.; Waugh, M.; Western Clinical School: Medicine (Westmead)Autografting followed by rituximab for chemosensitive mantle cell lymphoma: A pilot study and literature review., Leukemia & lymphoma, vol.46,(6),2005,pp 851-860
2014Clinical utility of Aspergillus galactomannan and PCR in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignanciesChen, Sharon; Halliday, Catriona; De Silva, Harini; Heng, Siow-Chin; Kong, D C M; Manser, Renee; Morrissey, Orla; Nation, Roger; Seymour, John F.; Slavin, Monica A.; Thursky, Karin; Western Clinical School: Medicine (Westmead); Molecular BioscienceClinical utility of Aspergillus galactomannan and PCR in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignancies, Diagnostic Microbiology and Infectious Disease, vol.79, 3, 2014,pp 322-327
2014Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.Iland, Harry; Seymour, John F.; Wei, Andrew; Central Clinical School: MedicineHave all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care., Best Practice & Research: Clinical Haematology, vol.27, 1, 2014,pp 39-52
2003Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly disgnosed chronic myeloid leukemia in chronic phaseBradstock, Kenneth; Arthur, C.; Branford, Susan; Browett, Peter; Durrant, Simon; Gathmann, I.; Grigg, Andrew P.; Harper, A.; Hughes, T. P.; Joske, D.; Lynch, Kevin; Ma, D.; Rudzki, Zbigniew; Schwarer, Anthony; Seymour, John F.; Taylor, Kerry; Western Clinical School: Westmead Millennium InstituteImatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly disgnosed chronic myeloid leukemia in chronic phase, Leukemia, vol.17,(12),2003,pp 2401-2409
2014Optimal approach for high-risk acute promyelocytic leukemiaIland, Harry; Seymour, John F.; Wei, Andrew; Central Clinical School: MedicineOptimal approach for high-risk acute promyelocytic leukemia, Current Opinion In Hematology, vol.21, 4, 2014,pp 102-113
2010Oseltamivir Resistance in Adult Oncology and Hematology Patients Infected with Pandemic (H1N1) 2009 Virus, AustraliaDwyer, Dominic; Wang, Bin; Buising, Kirsty L; Cheng, Allen C; Denholm, Justin T; Doyle, Joseph S; Ferguson, Patricia E; George, Biju; Harper, Janet M; Harrison, Simon James; Hurt, Aeron; Johnson, Paul D R; Langan, Katherine; Morrissey, C. O.; Reid, Alistair B; Seymour, John F.; Slavin, Monica; Thursky, Karin; Tramontana, Adrian R; Worth, Leon J; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium InstituteOseltamivir Resistance in Adult Oncology and Hematology Patients Infected with Pandemic (H1N1) 2009 Virus, Australia, Emerging Infectious Diseases, vol.16, 7, 2010,pp 1068-1075
2014A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemiaBradstock, Kenneth; Collins, Marnie; Cull, Gavin; Di Iulio, Juliana L.; Enno, Arno; Hahn, U; Lewis, Ian D.; Link, Emma; Marlton, P.; Schwarer, Anthony; Seymour, John F.; Szer, Jeff; Western Clinical School: Westmead Millennium InstituteA randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia, British Journal of Haematology, vol.167, 5, 2014,pp 618-625
2004Real-Time Quantitative Pcr Analysis Can Be Used As A Primary Screen To Identify Patients With Cml Treated With Imatinib Who Have Bcr-Abl Kinase Domain Mutations.Bradstock, Kenneth; Branford, Susan; Browett, Peter; Durrant, Simon; et, al; Grigg, Andrew P.; Parkinson, Ian; Rudzki, Zbigniew; Schwarer, Anthony; Seymour, John F.; Taylor, Kerry; Western Clinical School: Westmead Millennium InstituteReal-Time Quantitative Pcr Analysis Can Be Used As A Primary Screen To Identify Patients With Cml Treated With Imatinib Who Have Bcr-Abl Kinase Domain Mutations., Blood, vol.104,(9),2004,pp 2926-2932
2012Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemiaBradstock, Kenneth; Hertzberg, Mark; Iland, Harry; Brighton, Tim; Browett, Peter; Cannell, P; Catalano, J; Deveridge, Sandra; et al, various; Grigg, A; Horvath, Noemi; Seymour, John F.; Taylor, Kerry; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Central Clinical School: MedicineResults of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia, Haematologica: the hematology journal, vol.97, 2, 2012,pp 227-234
2011Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trialEstell, Jane; Belada, David; Bouabdallah, Réda; Brice, Pauline; Catalano, John Vincent; et al, various; Feugier, Pierre; López-Guillermo, Armando; Offner, Fritz; Salles, Gilles; Seymour, John F.; Xerri, Luc; Concord Clinical School: MedicineRituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, The Lancet, vol.377, 9759, 2011,pp 42-51
2013Role of arsenic trioxide in acute promyelocytic leukemiaIland, Harry; Seymour, John F.; Central Clinical School: MedicineRole of arsenic trioxide in acute promyelocytic leukemia, Current Treatment Options in Oncology, vol.14, 2, 2013,pp 170-184